2014-09-23T11:19:57-05:00 2013-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1700 BELLEVUE WA 98004 990 2013-01-01 911608978 INFECTIOUS DISEASE RESEARCH INSTITUTE INFE 2063810883 1616 EASTLAKE AVE E NO 400 SEATTLE WA 98102 ERIK IVERSON PRESIDENT, BUSINESS & OPERATIONS 2063810883 2014-09-22 1 JANE M SEARING P00000565 4254544919 2014-09-22 2013 2015-11-30 17:44:51Z ERIK IVERSON 1616 EASTLAKE AVE E NO 400 SEATTLE WA 98102 13888904 0 X WWW.IDRI.ORG X 1993 WA DEVELOP VACCINES, DIAGNOSTICS & DRUGS TO PREVENT, DETECT & TREAT INFECTIOUS DISEASES OF POVERTY. 9 7 148 7 250166 -405104 20127852 11743860 2779545 1460223 38260 -12487 10813 659384 22956470 13850980 16150 9500 0 0 10989760 11339831 0 24838 278692 13379680 14548947 24385590 25923116 -1429120 -12072136 49538156 45214688 12130421 19875890 37407735 25338798 X DEVELOP VACCINES, DIAGNOSTICS AND NOVEL DRUGS TO PREVENT, DETECT AND TREAT INFECTIOUS DISEASES OF POVERTY. 0 0 7271777 9500 223790 VACCINE RESEARCH - VACCINES ARE COMPOSED OF SEVERAL COMPONENTS: (A) ANTIGENS THAT STIMULATE THE IMMUNE SYSTEM TO COMBAT A PARTICULAR INFECTIOUS DISEASE AND (B) ADJUVANTS, SUBSTANCES THAT ENHANCE THE ABILITY OF ANTIGENS TO STIMULATE THE BODY'S IMMUNE RESPONSE. PUT ANOTHER WAY, ANTIGENS DETERMINE THE SPECIFICITY OF THE IMMUNE RESPONSE (E.G., FOR INFLUENZA OR TETANUS) WHEREAS ADJUVANTS AFFECT THE MAGNITUDE OF THE BODY'S IMMUNE RESPONSE.IDRI'S SCIENTISTS ARE USING THE LATEST TECHNIQUES TO IDENTIFY THE BEST ANTIGENS FOR NEW VACCINES TO COMBAT DISEASES THAT IMPACT GLOBAL HEALTH. IDRI'S CANDIDATE VACCINE FOR LEISHMANIASIS IS CURRENTLY IN CLINICAL TESTING AND VACCINES FOR TUBERCULOSIS AND LEPROSY ARE POISED TO START CLINICAL TESTING. 5229608 160942 ADJUVANT RESEARCH - AN IMPORTANT AREA OF RESEARCH FOR IDRI IS IMPROVING ADJUVANTS AND HOW THEY ARE COMBINED WITH ANTIGENS TO IMPROVE VACCINES. BETTER ADJUVANTS CAN INCREASE AND BROADEN THE IMMUNE RESPONSE TO AN ANTIGEN, AS WELL AS REDUCE THE AMOUNT OF ANTIGEN NECESSARY FOR A GOOD RESPONSE. THIS LAST CHARACTERISTIC CAN MAKE OUR VACCINE STOCKS GO FURTHER AND POTENTIALLY REDUCE THE COST. IDRI IS COLLABORATING WITH PARTNERS ALL OVER THE WORLD TO IMPROVE VACCINES FOR ADDITIONAL CHALLENGING DISEASES SUCH AS MALARIA AND PANDEMIC INFLUENZA. 3412284 105014 TUBERCULOSIS DRUG DISCOVERY - IN ADDITION TO WORKING ON BETTER DIAGNOSTIC TESTS AND VACCINES FOR TUBERCULOSIS (TB), IDRI HAS AN EARLY DISCOVERY PROGRAM TO IDENTIFY NEW CHEMICAL COMPOUNDS THAT ARE CANDIDATES TO TREAT TB. THERE IS AN URGENT NEED FOR NEW TYPES OF TB DRUGS; THE ONES CURRENTLY USED WERE DEVELOPED OVER 40 YEARS AGO AND WE ARE FACED WITH AN INCREASING THREAT FROM BACTERIA THAT ARE RESISTANT TO MANY OF THESE DRUGS. THE DRUG DISCOVERY GROUP COMBINES THE SKILLS OF MICROBIOLOGISTS, CHEMISTS, AND MOLECULAR BIOLOGISTS AND COLLABORATES WITH PHARMACEUTICAL COMPANIES AND OTHER RESEARCH INSTITUTIONS TO MAXIMIZE OUR CHANCE OF SUCCESS. 649308 844290 MANUFACTURING - ONCE A VACCINE CANDIDATE HAS BEEN IDENTIFIED IN THE RESEARCH LAB, THE NEXT CHALLENGE IS TO APPLY THAT DISCOVERY TO THE CLINICAL SETTING. A NECESSARY PART OF THIS TRANSITION IS TO PRODUCE VACCINES UNDER CONTROLLED CONDITIONS SO THAT THEY ARE SUITABLE FOR USE IN HUMAN STUDIES. IDRI HAS DEVELOPED THE TYPE OF MANUFACTURING CAPABILITY REQUIRED TO MOVE A VACCINE FROM LATE STAGE RESEARCH TO EARLY CLINICAL STUDIES. 3450927 126187 OTHER ACTIVITIES - IDRI'S CLINICAL GROUP DESIGNS AND CONDUCTS EARLY STAGE CLINICAL TRIALS TO TEST THE VACCINE CANDIDATES IDENTIFIED BY IDRI SCIENTISTS OR COLLABORATORS. THROUGH OUR NETWORK OF GLOBAL CONNECTIONS, THE CLINICAL TEAM IS ABLE TO LAUNCH CLINICAL TRIALS ALMOST ANYWHERE IN THE WORLD. 4100235 970477 20013904 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 1 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 63 0 1 148 1 1 1 0 0 0 0 0 0 0 0 0 X 9 7 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1 0 X X MARY BARSTAD 2063810883 1616 EASTLAKE AVE E SUITE 400 SEATTLE WA 98102 DAVID MAKI JD CHAIRMAN 5.00 X X 0 0 0 DAVID WEBSTER SECRETARY/TREASURER 5.00 X X 0 0 0 MASSIMO RADAELLI DIRECTOR 5.00 X 0 0 0 H STEWART PARKER CEO/DIRECTOR 40.00 X X 387295 0 11349 STEVEN REED PHD PRESIDENT & CSO/DIRECTOR 40.00 X X 369191 0 11349 ERIC EASOM DIRECTOR 5.00 X 0 0 0 CHRIS HENTSCHEL PHD DIRECTOR 5.00 X 0 0 0 DAVID PERRY DIRECTOR 5.00 X 0 0 0 FRANKLYN PRENDERGAST MD DIRECTOR 5.00 X 0 0 0 ROBERT LIN VP, FINANCE 40.00 X 147907 0 9385 CURT MALLOY SVP, OPERATIONS & GENERAL COUNSEL 40.00 X 213723 0 10374 ERIK IVERSON JD LLM EVP, BUSINESS DEVELOP & EXT AFFAIRS 40.00 X 229715 0 10449 ANNA MARIE BECKMANN VP, DEVELOPMENT & REGULATORY 40.00 X 159960 0 9465 RHEA COLER VP, PRE-CLINICAL BIOLOGY 40.00 X 157442 0 9249 JOSHUA ODINGO DIRECTOR, CHEMISTRY 40.00 X 134229 0 8406 THOMAS VEDVICK VP, FORMULATION/PROCESS DEVELOPMENT 40.00 X 131838 0 8309 WINSTON WICOMB DIRECTOR, VIVARIUM 40.00 X 143836 0 9199 2075136 0 97534 22 0 1 0 IIT RESEARCH INSTITUTE 10 WEST 35TH STREET 8TH FLOOR CHICAGO IL 60616 RESEARCH 665000 NATIONAL INSTITUTES OF HEALTH 9000 ROCKVILLE PIKE BETHESDA MD 20892 RESEARCH 517000 GENNOVA BIOPHARMACEUTICALS LIMITED T184 MIDC BHOSARI PUNE IN 411026 RESEARCH 500000 SAI ADVANTIUM PHARMA LTD BLD 1 PLOT 2 CHRYSALIS ENCLAVE PUNE IN 411027 RESEARCH 325000 CORDEN PHARMACEUTICALS EICHENWEG 1 LIESTAL SZ 4410 RESEARCH 215000 8 6685439 5058421 11743860 CONTRACT REVENUE 541700 844290 844290 VIVARIUM INCOME 541700 249841 249841 OPTION FEE REVENUE 541700 190000 190000 RESEARCH REVENUE 541700 176092 176092 1460223 25437 25437 658559 658559 325 0 325 325 325 37924 -37924 -37924 -37924 MISCELLANEOUS 900099 500 500 500 13850980 1210382 250166 646572 9500 9500 1400737 372185 941937 86615 8017853 5939343 1989305 89205 105719 89910 15779 30 1103472 839240 253610 10622 712050 530477 173740 7833 404321 226674 177647 51696 51696 24838 24838 125143 39694 85449 43445 2670 40775 319000 121069 176660 21271 212931 19481 193450 296234 296234 3017434 2400271 591680 25483 384434 233101 145870 5463 82875 26613 55775 487 1523424 1350033 166546 6845 77049 11959 65090 LAB SUPPLIES 3630867 3491482 139385 CONTRACTED SERVICES 3356743 3354924 1819 SUBCONTRACTS 603620 571878 31742 REPAIRS & MAINTENANCE 320580 238127 82453 99151 93577 5574 25923116 20013904 5630520 278692 4637406 819554 15811089 7605899 18171269 18484103 1231667 2398875 207037 197798 21470425 5762745 9478710 15707680 250 250 728 529 49538156 45214688 2445651 1503405 395055 286672 9289715 18085813 12130421 19875890 X 3085312 276042 34322423 25062756 37407735 25338798 49538156 45214688 -12072136 3199 0 X 0 1 X 1 1 1 X 6872037 11561223 14410786 20127852 11473860 64445758 6872037 11561223 14410786 20127852 11473860 64445758 23347847 41097911 1170237 1546290 1157313 896761 683996 5454597 45979 127472 173451 20502 184629 13705 500 219336 70293142 8301160 0.58470 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2009 AMOUNT: $ 20,502. 2013 AMOUNT: $ 500. REIMBURSEMENTS - 2010 AMOUNT: $ 25,419. 2011 AMOUNT: $ 12,502. PROPERTY TAX REFUND - 2010 AMOUNT: $ 159,210. REFUNDS - 2011 AMOUNT: $ 1,203. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 14811087 724248 14086839 6659338 5038497 1620841 15707680 DEFERRED RENT 18085813 18085813 13595869 3199 -296234 -293035 13888904 -37924 -37924 13850980 25664806 37924 37924 25626882 296234 296234 25923116 PART XI, LINE 2D - OTHER ADJUSTMENTS: ROYALTY EXPENSES INCLUDED IN INCOME ON FINANCIAL STATEMENTS -296,234. PART XI, LINE 4B - OTHER ADJUSTMENTS: LOSS ON DISPOSAL OF FIXED ASSETS -37,924. PART XII, LINE 2D - OTHER ADJUSTMENTS: LOSS ON DISPOSAL OF FIXED ASSETS 37,924. PART XII, LINE 4B - OTHER ADJUSTMENTS: ROYALTY EXPENSES INCLUDED IN INCOME ON FINANCIAL STATEMENTS 296,234. EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICES RESEARCH 479962 EAST ASIA AND THE PACIFIC - 0 0 PROGRAM SERVICES RESEARCH 184560 SOUTH AMERICA - ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLUMBIA, ECUADOR, 0 0 PROGRAM SERVICES RESEARCH 189980 MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 0 0 PROGRAM SERVICES RESEARCH 62202 SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA, FASO, 0 0 PROGRAM SERVICES RESEARCH 89900 SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL, 0 0 PROGRAM SERVICES RESEARCH 830025 NORTH AMERICA - CANADA AND MEXICO, BUT BUT NOT THE UNITED STATES 0 0 PROGRAM SERVICES RESEARCH 385 0 0 0 0 0 0 1837014 0 1837014 0 0 0 0 0 0 PART I, LINE 3: THE EXPENDITURES REPORTED ON SCHEDULE F, PART I, LINE 3 ARE ON ACCRUAL BASIS OF ACCOUNTING. X X X X X X 1 CORNERSTONE SOLUTIONS LLC 918 NW 52ND ST SEATTLE WA 98107 DEVELOP STRATEGY & TRAINING 0 0 24838 0 24838 WA 1 WHITMAN COLLEGE 345 BOYER AVENUE WALLA WALLA WA 99362 910567740 501(C)(3) 9000 0 N/A N/A GENERAL SUPPORT 1 0 PART I, LINE 2: ALL PAYMENTS MADE FOR PROGRAM SERVICES WITHIN THE U.S. ARE BASED ON LEGAL AGREEMENTS BETWEEN IDRI AND THE PARTY RECEIVING PAYMENT. THESE AGREEMENTS INCLUDE REQUIREMENTS FOR BOTH PROGRESS AND FINANCIAL REPORTING BASED ON TIME PERIODS OR MILESTONE ACHIEVEMENTS. REPORTS ARE REVIEWED BY SCIENTIFIC AND ADMINISTRATIVE STAFF TO ENSURE THAT THE GOALS OF THE AGREEMENT AND ANY SPECIFIC FINANCIAL RESTRICTIONS ARE BEING MET BEFORE FURTHER PAYMENT IS MADE. MOST AGREEMENTS ALSO CONTAIN A CLAUSE GIVING IDRI THE RIGHT TO AUDIT FINANCIAL RECORDS OF THE PARTY IF NEEDED. X X X X 0 0 0 0 0 0 0 0 0 H STEWART PARKER CEO/DIRECTOR 387295 0 0 0 0 0 5100 0 6249 0 398644 0 0 0 STEVEN REED PHD PRESIDENT & CSO/DIRECTOR 369191 0 0 0 0 0 5100 0 6249 0 380540 0 0 0 ROBERT LIN VP, FINANCE 147907 0 0 0 0 0 3136 0 6249 0 157292 0 0 0 CURT MALLOY SVP, OPERATIONS & GENERAL COUNSEL 213723 0 0 0 0 0 4125 0 6249 0 224097 0 0 0 ERIK IVERSON JD LLM EVP, BUSINESS DEVELOP & EXT AFFAIRS 229715 0 0 0 0 0 4200 0 6249 0 240164 0 0 0 ANNA MARIE BECKMANN VP, DEVELOPMENT & REGULATORY 159960 0 0 0 0 0 3216 0 6249 0 169425 0 0 0 RHEA COLER VP, PRE-CLINICAL BIOLOGY 157442 0 0 0 0 0 3000 0 6249 0 166691 0 0 0 WINSTON WICOMB DIRECTOR, VIVARIUM 143836 0 0 0 0 0 2950 0 6249 0 153035 0 0 0 FORM 990, PART 1, LINE 6: THERE WERE SEVEN VOLUNTEER BOARD MEMBERS DURING THE YEAR. BOARD MEMBERS PARTICIPATE IN STRATEGIC PLANNING, EXECUTIVE LEADERSHIP RECRUITMENT AND SELECTION, INTELLECTUAL PROPERTY STRATEGY, AND IDENTIFICATION OF INSTITUTIONAL LIABILITY. THEY COME FROM A VARIETY OF BACKGROUNDS AND DEMONSTRATE FINANCIAL EXPERTISE, REAL ESTATE LEASING/PURCHASING EXPERTISE, BIO-MEDICAL NOT-FOR-PROFIT EXPERTISE, AND AN UNDERSTANDING OF BUSINESS AND BIOTECH LICENSING. FORM 990, PART VI, SECTION A, LINE 8B BOARD MEETING MINUTES ARE DOCUMENTED AND APPROVED AT THE NEXT MEETING BY THE BOARD. COMMITTEE MEETINGS ARE NOT DOCUMENTED BY REQUEST OF THE COMMITTEE MEMBERS. FORM 990, PART VI, SECTION B, LINE 11 A DRAFT COPY OF THE FORM 990 AND FORM 990-T IS PRESENTED TO THE AUDIT COMMITTEE FOR REVIEW. THE AUDIT COMMITTEE REVIEWS AND APPROVES THE FORM 990 AND 990-T ON BEHALF OF THE IDRI BOARD OF DIRECTORS. ALL BOARD MEMBERS RECEIVE A COPY OF THE FORM 990 AND 990-T PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C EACH JANUARY, MEMBERS OF THE BOARD OF DIRECTORS AND SENIOR MANAGEMENT ARE GIVEN A COPY OF THE CONFLICT OF INTEREST POLICY. THEY ARE REQUIRED TO FILL IT OUT AND RETURN IT BY THE FIRST BOARD MEETING - USUALLY SOMETIME IN THE FIRST QUARTER. THE SENIOR VICE PRESIDENT OF OPERATIONS AND GENERAL COUNSEL REVIEWS THE QUESTIONNAIRES AND SUMMARIZES THE RESULTS. THE RESULTS ARE COMMUNICATED TO THE BOARD OF DIRECTORS. TO THE EXTENT THAT THERE ARE ANY CONFLICTS, THE MEMBER IS RECUSED FROM ANY DECISION MAKING THAT WOULD INCLUDE THE CONFLICT. WHEN THE OCCASION ARISES, THOSE MEMBERS ALSO REMIND THE GROUP (MANAGEMENT TEAM OR BOARD) THAT THERE IS A POTENTIAL CONFLICT WHEN SPECIFIC DISCUSSION TOPICS ARISE. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE CONDUCTED A FULL CEO PERFORMANCE AND COMPENSATION REVIEW, INITIATED IN JANUARY 2013 WITH A REPORT AT THE APRIL 2013 BOARD MEETING, USING AN OUTSIDE INDEPENDENT CONSULTANT. THE REPORT IS IN THE BOARD MATERIALS AND IN THE PERSONNEL FILE. THE DECISIONS ARE IN THE COMPENSATION COMMITTEE NOTES. COMPARATIVE COMPENSATION INFORMATION WAS USED FROM THE CULPEPPER AND RADFORD PROFESSIONAL COMPENSATION FIRMS. THE BOARD CHAIR ALSO DOES AN ANNUAL REVIEW OF ALL OTHER OFFICERS AND KEY EMPLOYEES AND WORKS WITH THE HUMAN RESOURCES DEPARTMENT TO DETERMINE IF THE COMPENSATION IS ADEQUATE. IF AN ADJUSTMENT IS DEEMED NECESSARY, THE BOARD CHAIR CONVENES THE COMPENSATION COMMITTEE AND THE ADJUSTMENT IS ADDRESSED. THE BOARD CHAIR REPORTS BACK TO THE HUMAN RESOURCES DEPARTMENT WHO FOLLOWS THROUGH WITH THE COMMITTEE'S RECOMMENDATION. FORM 990, PART VI, SECTION C, LINE 19 THE IDRI AUDITED FINANCIAL STATEMENTS ARE AVAILABLE ON OUR WEBSITE, WWW.IDRI.ORG. REQUESTS FOR OTHER INFORMATION SUCH AS GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE HANDLED THROUGH OUR FINANCE DEPARTMENT AND INFORMATION IS DISTRIBUTED AS REQUESTED UNLESS CONFIDENTIAL IN NATURE.